2025年2月25日,医疗健康公司惠森股份(Hims & Hers Health Inc,股票代码HIMS)盘中出现大幅度下跌,跌幅高达25.33%,引发了市场广泛关注。
此次惠森股价大跌的主要原因包括两个方面:首先,FDA宣布减肥药Wegovy供应短缺问题已获解决,这可能会限制惠森继续在其线上平台销售该药物的复方版本,对其减肥药业务的收入带来重大影响。其次,惠森第四季度财报显示,毛利率低于预期,引发市场对其未来获利能力的担忧。
惠森在此前的财报中曾预计2025年减肥药业务收入可达7.25亿美元,但随着Wegovy供应恢复正常及毛利率低于预期,市场开始质疑这一预期是否过于乐观。分析师普遍认为惠森在减肥药领域的业务可能将受到重创,未来增长前景存在不确定性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.